- Multikinase inhibitor, targetting Raf kinase and possibly other kinase activation by VEGF 1, 2, and 3, PDGFRβ, FLT3, c-KIT and RET
- Indications include renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid carcinoma, as well as certain types of acute myeloid leukemia
- Can cause myelosuppression
